Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (12): 1224-1228.DOI: 10.3969/j.issn.1673-8640.2024.12.016
Previous Articles Next Articles
ZHOU He, DONG Wanjiang, LUO Zhong
Received:
2023-02-17
Revised:
2024-06-24
Online:
2024-12-30
Published:
2025-01-06
CLC Number:
ZHOU He, DONG Wanjiang, LUO Zhong. Predictive roles of serum MIP-1α and hBD3 in postoperative endophthalmitis of cataract patients[J]. Laboratory Medicine, 2024, 39(12): 1224-1228.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.12.016
组别 | 例数 | 年龄/岁 | 性别 | BMI/(kg·m-2) | 高血压史/[例(%)] | 糖尿病史/[例(%)] | SBP/kPa | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
男/ [例(%)] | 女/ [例(%)] | ||||||||||
无眼内炎组 | 144 | 64.84±3.55 | 82(56.94) | 62(43.06) | 22.37±2.11 | 53(36.81) | 46(31.94) | 16.51±1.48 | |||
眼内炎组 | 18 | 65.72±3.71 | 13(72.22) | 5(27.78) | 23.02±2.63 | 8(44.44) | 6(33.33) | 16.75±1.38 | |||
对照组 | 98 | 65.49±3.75 | 52(53.06) | 46(46.94) | 22.85±2.73 | 41(41.84) | 25(25.51) | 16.54±1.59 | |||
统计值 | 1.172 | 2.294 | 1.471 | 0.824 | 1.286 | 0.201 | |||||
P值 | 0.311 | 0.318 | 0.232 | 0.662 | 0.526 | 0.818 | |||||
组别 | DBP/kPa | TG/(mmoL·L-1) | TC/(mmoL·L-1) | HDL-C/(mmoL·L-1) | LDL-C/(mmoL·L-1) | 术前MIP-1α/(ng·L-1) | 术前hBD3/(μg·L-1) | ||||
无眼内炎组 | 10.64±1.26 | 1.58±0.32 | 4.23±1.17 | 1.23±0.45 | 2.38±0.79 | 32.28±6.03 | 4.67±1.47 | ||||
眼内炎组 | 10.92±1.31 | 1.60±0.47 | 4.30±1.34 | 1.28±0.53 | 2.26±0.65 | 56.21±12.06 | 2.19±0.54 | ||||
对照组 | 10.93±1.33 | 1.57±0.41 | 4.21±1.01 | 1.29±0.51 | 2.30±0.70 | 17.59±4.11 | 6.81±1.92 | ||||
统计值 | 1.606 | 0.057 | 0.050 | 0.482 | 0.448 | 380.101 | 87.006 | ||||
P值 | 0.203 | 0.944 | 0.952 | 0.618 | 0.639 | <0.001 | <0.001 |
组别 | 例数 | 年龄/岁 | 性别 | BMI/(kg·m-2) | 高血压史/[例(%)] | 糖尿病史/[例(%)] | SBP/kPa | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
男/ [例(%)] | 女/ [例(%)] | ||||||||||
无眼内炎组 | 144 | 64.84±3.55 | 82(56.94) | 62(43.06) | 22.37±2.11 | 53(36.81) | 46(31.94) | 16.51±1.48 | |||
眼内炎组 | 18 | 65.72±3.71 | 13(72.22) | 5(27.78) | 23.02±2.63 | 8(44.44) | 6(33.33) | 16.75±1.38 | |||
对照组 | 98 | 65.49±3.75 | 52(53.06) | 46(46.94) | 22.85±2.73 | 41(41.84) | 25(25.51) | 16.54±1.59 | |||
统计值 | 1.172 | 2.294 | 1.471 | 0.824 | 1.286 | 0.201 | |||||
P值 | 0.311 | 0.318 | 0.232 | 0.662 | 0.526 | 0.818 | |||||
组别 | DBP/kPa | TG/(mmoL·L-1) | TC/(mmoL·L-1) | HDL-C/(mmoL·L-1) | LDL-C/(mmoL·L-1) | 术前MIP-1α/(ng·L-1) | 术前hBD3/(μg·L-1) | ||||
无眼内炎组 | 10.64±1.26 | 1.58±0.32 | 4.23±1.17 | 1.23±0.45 | 2.38±0.79 | 32.28±6.03 | 4.67±1.47 | ||||
眼内炎组 | 10.92±1.31 | 1.60±0.47 | 4.30±1.34 | 1.28±0.53 | 2.26±0.65 | 56.21±12.06 | 2.19±0.54 | ||||
对照组 | 10.93±1.33 | 1.57±0.41 | 4.21±1.01 | 1.29±0.51 | 2.30±0.70 | 17.59±4.11 | 6.81±1.92 | ||||
统计值 | 1.606 | 0.057 | 0.050 | 0.482 | 0.448 | 380.101 | 87.006 | ||||
P值 | 0.203 | 0.944 | 0.952 | 0.618 | 0.639 | <0.001 | <0.001 |
组别 | 例数 | MIP-1α | F值 | P值 | |||
---|---|---|---|---|---|---|---|
术前/(ng·L-1) | 术后1 d/(ng·L-1) | 术后3 d/(ng·L-1) | 术后7 d/(ng·L-1) | ||||
无眼内炎组 | 144 | 32.28±6.03 | 19.34±4.35* | 20.17±5.36* | 20.34±5.72* | 1 540.59 | <0.001 |
眼内炎组 | 18 | 56.21±12.06 | 50.22±10.96* | 53.76±11.75* | 55.21±12.18* | 1 326.59 | <0.001 |
t值 | 13.823 | 22.675 | 21.153 | 20.791 | |||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | MIP-1α | F值 | P值 | |||
---|---|---|---|---|---|---|---|
术前/(ng·L-1) | 术后1 d/(ng·L-1) | 术后3 d/(ng·L-1) | 术后7 d/(ng·L-1) | ||||
无眼内炎组 | 144 | 32.28±6.03 | 19.34±4.35* | 20.17±5.36* | 20.34±5.72* | 1 540.59 | <0.001 |
眼内炎组 | 18 | 56.21±12.06 | 50.22±10.96* | 53.76±11.75* | 55.21±12.18* | 1 326.59 | <0.001 |
t值 | 13.823 | 22.675 | 21.153 | 20.791 | |||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | hBD3 | F值 | P值 | |||
---|---|---|---|---|---|---|---|
术前/(μg·L-1) | 术后1 d/(μg·L-1) | 术后3 d/(μg·L-1) | 术后7 d/(μg·L-1) | ||||
无眼内炎组 | 144 | 4.67±1.47 | 5.07±1.29* | 5.12±1.41* | 5.09±1.22* | 1 250.49 | <0.001 |
眼内炎组 | 18 | 2.19±0.54 | 3.37±0.95* | 3.20±0.69* | 3.07±0.78* | 1 321.54 | <0.001 |
t值 | 7.082 | 5.404 | 5.681 | 6.841 | |||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | hBD3 | F值 | P值 | |||
---|---|---|---|---|---|---|---|
术前/(μg·L-1) | 术后1 d/(μg·L-1) | 术后3 d/(μg·L-1) | 术后7 d/(μg·L-1) | ||||
无眼内炎组 | 144 | 4.67±1.47 | 5.07±1.29* | 5.12±1.41* | 5.09±1.22* | 1 250.49 | <0.001 |
眼内炎组 | 18 | 2.19±0.54 | 3.37±0.95* | 3.20±0.69* | 3.07±0.78* | 1 321.54 | <0.001 |
t值 | 7.082 | 5.404 | 5.681 | 6.841 | |||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
变量 | β值 | 标准误 | Wald值 | P值 | OR①值(95%CI②) |
---|---|---|---|---|---|
MIP-1α | 0.512 | 0.183 | 7.816 | 0.005 | 1.668(1.165~2.387) |
hBD3 | -0.214 | 0.102 | 4.420 | 0.036 | 0.807(0.661~0.986) |
变量 | β值 | 标准误 | Wald值 | P值 | OR①值(95%CI②) |
---|---|---|---|---|---|
MIP-1α | 0.512 | 0.183 | 7.816 | 0.005 | 1.668(1.165~2.387) |
hBD3 | -0.214 | 0.102 | 4.420 | 0.036 | 0.807(0.661~0.986) |
指标 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
MIP-1α | 0.769(0.696~0.831) | 45.86 ng·L-1 | 72.22 | 80.56 | 0.528 |
hBD3 | 0.819(0.751~0.875) | 3.51 μg·L-1 | 88.89 | 72.22 | 0.611 |
二者联合 | 0.954(0.909~0.980) | 0.42 | 94.44 | 88.19 | 0.826 |
指标 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
MIP-1α | 0.769(0.696~0.831) | 45.86 ng·L-1 | 72.22 | 80.56 | 0.528 |
hBD3 | 0.819(0.751~0.875) | 3.51 μg·L-1 | 88.89 | 72.22 | 0.611 |
二者联合 | 0.954(0.909~0.980) | 0.42 | 94.44 | 88.19 | 0.826 |
[1] | 江立. 血清sTREM-1,sCD14和PCT水平对白内障术后患者眼内炎及前房积脓的诊断价值[J]. 检验医学与临床, 2022, 19(16):2215-2219. |
[2] | 郑娟. 白内障患者手术后并发感染性眼内炎的相关因素及围手术期护理效果[J]. 东方药膳, 2021(9):183. |
[3] | 邹玉凌, 陈佳, 游志鹏. 193例感染性眼内炎患者致病原因及临床特点分析[J]. 眼科新进展, 2021, 41(10):948-951. |
[4] | 刘夕瑶, 毛菲菲, 李丹, 等. 获得性免疫缺陷综合征合并内源性眼内炎患者临床特征分析[J]. 眼科, 2021, 30(4):290-294. |
[5] | HUANG S M, HU W J, RAO D M, et al. RIPK3-dependent necroptosis activates MCP-1-mediated inflammation in mice after intracerebral hemorrhage[J]. J Stroke Cerebrovasc Dis, 2022, 31(1):106213. |
[6] |
王雅玲, 黄运丽, 田密, 等. 急性支气管肺炎患儿EOS%、CCR3、Eotaxin与病情严重程度的关系[J]. 检验医学, 2023, 38(3):230-234.
DOI |
[7] | 陶海娃, 叶晓洁, 林小容, 等. MCP-1 mRNA和MIP-1αmRNA表达与阿尔茨海默病晚期合并肺部感染的关系[J]. 中华医院感染学杂志, 2022, 32(11):1654-1658. |
[8] | YOO Y J, PERINPANAYAGAM H, LEE J Y, et al. Synthetic human β defensin-3-C15 peptide in endodontics:potential therapeutic agent in Streptococcus gordonii lipoprotein-stimulated human dental pulp-derived cells[J]. Int J Mol Sci, 2019, 21(1):71. |
[9] | OLSON R J, BRAGA-MELE R, CHEN S H, et al. Cataract in the adult eye preferred practice pattern®[J]. Ophthalmology, 2017, 124(2):P1-P119. |
[10] | 中华医学会眼科学分会白内障与人工晶状体学组. 我国白内障术后急性细菌性眼内炎治疗专家共识(2010年)[J]. 中华眼科杂志, 2010, 46(8):764-766. |
[11] | 庄悦妍. 康复护理对白内障患者术后感染性眼内炎的效果[J]. 反射疗法与康复医学, 2021, 2(1):83-85. |
[12] | 符郁, 岑育健, 符密, 等. 血清PCT和hs-CRP水平及CD64指数在白内障术后感染性眼内炎诊断中的应用[J]. 中华医院感染学杂志, 2019, 29(23):3614-3617. |
[13] | 林惠军, 龚潇, 杨倩. 血清淀粉样蛋白A、高迁移率族蛋白1、CD64指数在白内障患者术后眼内炎诊断中的应用[J]. 眼科新进展, 2021, 41(2):158-162. |
[14] |
AHMAD R, AKHTER N, ROUB A, et al. MIP-1α induction by palmitate in the human monocytic cells implicates TLR4 signaling mechanism[J]. Cell Physiol Biochem, 2019, 52(2):212-224.
DOI PMID |
[15] | 程春生, 李纲. 纤维支气管镜肺泡灌洗对重症肺炎伴呼吸衰竭患者炎性反应介质因子的影响[J]. 吉林医学, 2018, 39(4):656-658. |
[16] | 张金仿, 王刚, 高琰, 等. 腺病毒肺炎患儿血清MIP-1α和外周血SOCS-1 mRNA,SOCS-3 mRNA的变化及意义[J]. 临床和实验医学杂志, 2020, 19(15):1582-1585. |
[17] | RAINA M, BATES A M, FISCHER C L, et al. Human beta defensin 3 alters matrix metallo proteinase production in human dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B[J]. J Periodontol, 2018, 89(3):361-369. |
[18] | 张丽媛, 张鹏, 马婷婷. 龈沟液SFRP1、hBD3、肿瘤坏死因子-α在慢性牙周炎伴Hp感染患者中表达及临床意义[J]. 分子诊断与治疗杂志, 2021, 13(2):296-299. |
[1] | Beijing Medical Association Laboratory Medicine Branch, Shanghai Medical Association Laboratory Medicine Branch. Expert consensus on interference factors and solutions for immunological testing [J]. Laboratory Medicine, 2024, 39(12): 1131-1139. |
[2] | WANG Ziwen, WU Wenjuan. Research progress on determination and mechanism of drug resistance and tolerance to Cryptococcus neoformans [J]. Laboratory Medicine, 2024, 39(12): 1140-1144. |
[3] | XU Chunhui, ZHOU Xinyue, YI Huiming, ZHANG Lining, CHEN Shulian, ZHU Guoqing, FENG Sizhou. Diagnostic roles of mNGS and Mucorales PCR in pulmonary mucormycosis in patients with blood diseases [J]. Laboratory Medicine, 2024, 39(12): 1145-1149. |
[4] | LIU Ruiguang, GUO Jian. Hospital and external environmental fungal screening and drug susceptibility analysis [J]. Laboratory Medicine, 2024, 39(12): 1150-1156. |
[5] | WANG Dongjiang, HU Liang, GUO Jian, LI Teng, TIAN Wenjie, YANG Simin, ZHANG Min, LIN Huiping, WAN Feifei, WANG Ziwen, ZHOU Aiping. Drug resistance in clinical isolates of Candida parapsilosis species complex in eastern China region from 2017 to 2023 [J]. Laboratory Medicine, 2024, 39(12): 1163-1168. |
[6] | ZHU Xiaoyu, LI Zhiwei, JIA Jintong, LI Shuling, LIU Yezi, WANG Lingling, WANG Qian, LU Peipei, SHI Qinghai. Peripheral blood expressions of PD-1,LAG-3 and related cytokines in patients with acute and chronic brucellosis [J]. Laboratory Medicine, 2024, 39(12): 1173-1180. |
[7] | ZOU Chen, XU Runhao, DING Yi, ZHANG Jie, WENG Wenhao, WANG Zhenhua, CAO Yun. Colorectal cancer screening model based on ProteomeXchange database [J]. Laboratory Medicine, 2024, 39(12): 1181-1189. |
[8] | SHEN Zhan, BIAN Xiaobo, HUANG Ying, WANG Siyang, SHEN Tingting, ZHANG Xian, SONG Yunxiao, XIE Lianhong. Stroke recurrence prediction model based on machine learning algorithms using routine blood test [J]. Laboratory Medicine, 2024, 39(12): 1190-1195. |
[9] | JIN Zhonggan, LU Liu, YE Zhihan, JU Yi, OU Yuanzhu, YU Xiaoxuan, ZHANG Sujie. Development and application of quality control materials for GCA in serum [J]. Laboratory Medicine, 2024, 39(12): 1208-1213. |
[10] | WANG Yichun, LAN Xinqiang. Effect of preterm birth and low birth weight on 17α-OHP level and its cut-off value in screening neonatal genetic metabolic diseases in Weihai [J]. Laboratory Medicine, 2024, 39(12): 1214-1218. |
[11] | SONG Beiling, WU Jiong, HU Jiahua, WANG Yufei. Influence of common hemoglobin variants on different glycated hemoglobin determination systems [J]. Laboratory Medicine, 2024, 39(12): 1219-1223. |
[12] | CUI Xiaoyang, LIU Guodong, GUO Huijuan, LIAO Zhihong, LIU Yunhong, ZHANG Weifen, CHEN Zirao, WEI Xiaozhu. Roles of serum exosomal CEA,CA15-3 and CA125 in the differential diagnosis of non-small cell lung cancer and benign lung diseases [J]. Laboratory Medicine, 2024, 39(11): 1035-1041. |
[13] | ZHAO Qiang, XU Xiuwen, HAN Jiaojiao, SONG Ying, MIAO Yingbo, ZHU Peichao, ZHOU Wei, LIN Shiyang, TONG Lanfei, CHE Yiming, JIN Lei, XU Chong. Effect of different preservation methods on stability of samples in external quality assessment of paroxysmal nocturnal hemoglobinuria by flow cytometry [J]. Laboratory Medicine, 2024, 39(11): 1048-1052. |
[14] | LI Sirui, XU Junyue. Correlation between serum ESM1,DHEA-S and cardiac autonomic neuropathy in patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2024, 39(11): 1078-1083. |
[15] | SUN Jiangman, LI Min, MENG Xiangzhao, MA Li, ZHAO Guanglun, YU Hongyuan. Application of total protein standard reference material in frozen human serum in value transfer of reference method [J]. Laboratory Medicine, 2024, 39(11): 1118-1121. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||